Saga Communications, Inc. Declares a Quarterly Cash Dividend of $0.25 per Share
GROSSE POINTE FARMS, Mich., May 22, 2024 (GLOBE NEWSWIRE) — Saga Communications, Inc. (Nasdaq – SGA) (the “Company”, “Saga” or “our”) […]
Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference
NEWPORT BEACH, Calif., May 22, 2024 (GLOBE NEWSWIRE) — Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering […]
Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
GAITHERSBURG, Md., May 22, 2024 (GLOBE NEWSWIRE) — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty […]
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
Deal provides Cytokinetics with diversified access to capital as company advances its specialty cardiology franchise NEW YORK and SOUTH SAN […]
Nyxoah Announces Reduction of the Maximum Amount Available Under its At the-Market Equity Offering Program
REGULATED INFORMATIONINSIDE INFORMATION Nyxoah Announces Reduction of the Maximum Amount Available Under its At-the-Market Equity Offering Program Mont-Saint-Guibert, Belgium – […]
GlobalFoundries Announces Launch of $950 Million Secondary Offering of Ordinary Shares, Including Concurrent $200 Million Share Repurchase
MALTA, N.Y., May 22, 2024 (GLOBE NEWSWIRE) — GlobalFoundries Inc. (“GlobalFoundries” or “GF”) (Nasdaq: GFS) today announced the launch of […]
Western New England Bancorp, Inc. Announces Authorization of Repurchase Plan
WESTFIELD, Mass., May 22, 2024 (GLOBE NEWSWIRE) — Western New England Bancorp, Inc. (the “Company” or “WNEB”) (NasdaqGS: WNEB), the […]
ThredUp to Participate in William Blair Conference
OAKLAND, Calif., May 22, 2024 (GLOBE NEWSWIRE) — ThredUp (NASDAQ: TDUP, LTSE: TDUP), one of the largest online resale platforms […]
Akoustis Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Charlotte, N.C., May 22, 2024 (GLOBE NEWSWIRE) — Akoustis Technologies, Inc. (Nasdaq: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer (IDM) […]
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical studies including an asthma […]
